Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Epigenetics | Research

Interaction between a diabetes-related methylation site (TXNIP cg19693031) and variant (GLUT1 rs841853) on fasting blood glucose levels among non-diabetics

Authors: Hao-Hung Tsai, Chao-Yu Shen, Chien-Chang Ho, Shu-Yi Hsu, Disline Manli Tantoh, Oswald Ndi Nfor, Shin-Lin Chiu, Ying-Hsiang Chou, Yung-Po Liaw

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Type 2 diabetes mellitus (T2DM) is caused by a combination of environmental, genetic, and epigenetic factors including, fasting blood glucose (FBG), genetic variant rs841853, and cg19693031 methylation. We evaluated the interaction between rs841853 and cg19693031 on the FBG levels of non-diabetic Taiwanese adults.

Methods

We used Taiwan Biobank (TWB) data collected between 2008 and 2016. The TWB data source contains information on basic demographics, personal lifestyles, medical history, methylation, and genotype. The study participants included 1300 people with DNA methylation data. The association of cg19693031 methylation (stratified into quartiles) with rs841853 and FBG was determined using multiple linear regression analysis. The beta-coefficients (β) and p-values were estimated.

Results

The mean ± standard deviation (SD) of FBG in rs841853-CC individuals (92.07 ± 7.78) did not differ significantly from that in the CA + AA individuals (91.62 ± 7.14). However, the cg19693031 methylation levels were significantly different in the two groups (0.7716 ± 0.05 in CC individuals and 0.7631 ± 0.05 in CA + AA individuals (p = 0.002). The cg19693031 methylation levels according to quartiles were β < 0.738592 (< Q1), 0.738592 ≤ 0.769992 (Q1–Q2), 0.769992 ≤ 0.800918 (Q2–Q3), and β ≥ 0.800918 (≥ Q3). FBG increased with decreasing cg19693031 methylation levels in a dose–response manner (ptrend = 0.005). The β-coefficient was − 0.0236 (p = 0.965) for Q2–Q3, 1.0317 (p = 0.058) for Q1–Q2, and 1.3336 (p = 0.019 for < Q1 compared to the reference quartile (≥ Q3). The genetic variant rs841853 was not significantly associated with FBG. However, its interaction with cg19693031 methylation was significant (p-value = 0.036). Based on stratification by rs841853 genotypes, only the CC group retained the inverse and dose–response association between FBG and cg19693031 methylation. The β (p-value) was 0.8082 (0.255) for Q2–Q3, 1.6930 (0.022) for Q1–Q2, and 2.2190 (0.004) for < Q1 compared to the reference quartile (≥ Q3). The ptrend was 0.002.

Conclusion

Summarily, methylation at cg19693031 was inversely associated with fasting blood glucose in a dose-dependent manner. The inverse association was more prominent in rs841853-CC individuals, suggesting that rs841853 could modulate the association between cg19693031 methylation and FBG. Our results suggest that genetic variants may be involved in epigenetic mechanisms associated with FBG, a hallmark of diabetes. Therefore, integrating genetic and epigenetic data may provide more insight into the early-onset of diabetes.
Appendix
Available only for authorised users
Literature
1.
Ramtahal R, Khan C, Maharaj-Khan K, Nallamothu S, Hinds A, Dhanoo A, et al. Prevalence of self-reported sleep duration and sleep habits in type 2 diabetes patients in South Trinidad. J Epidemiol Global Health. 2015;5 (4):S35–43.
2.
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes–global burden of disease and forecasted trends. J Epidemiol Global Health. 2020;10 (1):107.
3.
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94 (3):311–21.PubMed
4.
Meeks KA, Henneman P, Venema A, Addo J, Bahendeka S, Burr T, et al. Epigenome-wide association study in whole blood on type 2 diabetes among sub-Saharan African individuals: findings from the RODAM study. Int J Epidemiol. 2019;48 (1):58–70.PubMed
5.
Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40 (5):638–45.PubMedPubMedCentral
6.
Drong A, Lindgren C, McCarthy M. The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther. 2012;92 (6):707–15.PubMed
7.
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42 (7):579–89.PubMedPubMedCentral
8.
Oluyombo R, Olamoyegun MA, Olaifa O, Iwuala SO, Babatunde OA. Cardiovascular risk factors in semi-urban communities in southwest Nigeria: patterns and prevalence. J Epidemiol Global Health. 2015;5 (2):167–74.
9.
Lone S, Lone K, Khan S, Pampori RA. Assessment of metabolic syndrome in Kashmiri population with type 2 diabetes employing the standard criteria’s given by WHO, NCEPATP III and IDF. J Epidemiol Global Health. 2017;7 (4):235–9.
10.
Mahanta TG, Joshi R, Mahanta BN, Xavier D. Prevalence of modifiable cardiovascular risk factors among tea garden and general population in Dibrugarh, Assam, India. J Epidemiol Global Health. 2013;3 (3):147–56.
11.
Bo A, Thomsen R, Nielsen J, Nicolaisen SK, Beck-Nielsen H, Rungby J, et al. Early-onset type 2 diabetes: age gradient in clinical and behavioural risk factors in 5115 persons with newly diagnosed type 2 diabetes—results from the DD2 study. Diabetes/Metab Res Rev. 2018;34 (3):e2968.
12.
Pippitt K, Li M, Gurgle HE. Diabetes mellitus: screening and diagnosis. Am Fam Physician. 2016;93 (2):103–9.PubMed
13.
Al Slail FY, Abid O, Assiri AM, Memish ZA, Ali MK. Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. J Epidemiol Global Health. 2016;6 (1):29–36.
14.
15.
Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease?: a meta-analysis of prospective studies. Arch Intern Med. 2004;164 (19):2147–55.PubMed
16.
Galochkina T, Chong MNF, Challali L, Abbar S, Etchebest C. New insights into GluT1 mechanics during glucose transfer. Sci Rep. 2019;9 (1):1–14.
17.
Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell. 2013;49 (6):1167–75.PubMedPubMedCentral
18.
Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, Poulsen P, et al. TXNIP regulates peripheral glucose metabolism in humans. PLoS Med. 2007;4 (5):e158.PubMedPubMedCentral
19.
Beg M, Zhang W, McCourt AC, Enerbäck S. ATGL activity regulates GLUT1-mediated glucose uptake and lactate production via TXNIP stability in adipocytes. J Biol Chem. 2021;296:100332.PubMedPubMedCentral
20.
Waldhart AN, Dykstra H, Peck AS, Boguslawski EA, Madaj ZB, Wen J, et al. Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. Cell Rep. 2017;19 (10):2005–13.PubMedPubMedCentral
21.
Wondafrash DZ, Nire’a AT, Tafere GG, Desta DM, Berhe DA, Zewdie KA. Thioredoxin-interacting protein as a novel potential therapeutic target in diabetes mellitus and its underlying complications. Diabetes Metab Syndr Obesity Targets Therapy. 2020;13:43.
22.
Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, Mola-Caminal M, Vivanco-Hidalgo RM, Ois A, et al. Epigenome-wide association study identifies TXNIP gene associated with type 2 diabetes mellitus and sustained hyperglycemia. Hum Mol Genet. 2016;25 (3):609–19.PubMed
23.
Walaszczyk E, Luijten M, Spijkerman AM, Bonder MJ, Lutgers HL, Snieder H, et al. DNA methylation markers associated with type 2 diabetes, fasting glucose and HbA 1c levels: a systematic review and replication in a case–control sample of the Lifelines study. Diabetologia. 2018;61 (2):354–68.PubMed
24.
Ramadan RA, Zaki AM, Magour GM, Zaki MA, Aglan SA, Madkour MA, et al. Association of XbaI GLUT1 polymorphism with susceptibility to type 2 diabetes mellitus and diabetic nephropathy. Am J Mol Biol. 2016;6:71–8.
25.
Du B, Liu S, Cui C, Wang S, Cui W. Association between glucose transporter 1 rs841853 polymorphism and type 2 diabetes mellitus risk may be population specific (葡萄糖转移酶 1 的 rs841853 基因多态性与 2 型糖尿发生风险的关系可能具有人群特异性). J Diabetes. 2013;5 (3):291–9.PubMed
26.
Stefanidis I, Tziastoudi M, Tsironi E, Dardiotis E, Tachmitzi S, Fotiadou A, et al. The contribution of genetic variants of SLC2A1 gene in T2DM and T2DM-nephropathy: association study and meta-analysis. Ren Fail. 2018;40 (1):561–76.PubMedPubMedCentral
27.
Mooyaart AL. Diabetic nephropathy: pathology, genetics and carnosine metabolism. Leiden: Leiden University; 2011.
28.
Liu Z-H, Guan T-J, Chen Z-H, Li L-S. Glucose transporter (GLUT1) allele (XbaI–) associated with nephropathy in non-insulin-dependent diabetes mellitus. Kidney Int. 1999;55 (5):1843–8.PubMed
29.
Grzeszczak W, Moczulski DK, Zychma M, Zukowska-Szczechowska E, Trautsolt W, Szydlowska I. Role of GLUT1 gene in susceptibility to diabetic nephropathy in type 2 diabetes. Kidney Int. 2001;59 (2):631–6.PubMed
30.
Stefanidis I, Kytoudis K, Papathanasiou AA, Zaragotas D, Melistas L, Kitsios GD, et al. XbaI GLUT1 gene polymorphism and the risk of type 2 diabetes with nephropathy. Dis Markers. 2009;27 (1):29–35.PubMedPubMedCentral
31.
Zintzaras E, Stefanidis I. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet. 2005;50 (2):84–91.PubMed
32.
Cui W, Du B, Zhou W, Jia Y, Sun G, Sun J, et al. Relationship between five GLUT1 gene single nucleotide polymorphisms and diabetic nephropathy: a systematic review and meta-analysis. Mol Biol Rep. 2012;39 (8):8551–8.PubMed
33.
Tao T, Tanizawa Y, Matsutani A, Matsubara A, Kaneko T, Kaku K. HepG2/erythrocyte glucose transporter (GLUT1) gene in NIDDM: a population association study and molecular scanning in Japanese subjects. Diabetologia. 1995;38 (8):942–7.PubMed
34.
Makni K, Mnif F, Boudawara M, Hamza N, Rekik N, Abid M, et al. Association of glucose transporter 1 polymorphisms with type 2 diabetes in the Tunisian population. Diabetes Metab Res Rev. 2008;24 (7):544–8.PubMed
35.
Bappy HJA, Goswami A, Huda N, Hosen MI, Nabi AN. Gender specific association of missense variant rs1805097 of IRS-2 and noncoding variant rs841853 of GLUT-1 genes with susceptibility to type 2 diabetes in Bangladeshi population. Gene Rep. 2020;21:100866.
36.
Liu H, Li S, Wang X, Zhu J, Wei Y, Wang Y, et al. DNA methylation dynamics: identification and functional annotation. Brief Funct Genomics. 2016;15 (6):470–84.PubMed
37.
Tantoh DM, Lee K-J, Nfor ON, Liaw Y-C, Lin C, Chu H-W, et al. Methylation at cg05575921 of a smoking-related gene (AHRR) in non-smoking Taiwanese adults residing in areas with different PM 2.5 concentrations. Clin Epigenet. 2019;11 (1):1–8.
38.
Fraser HB, Lam LL, Neumann SM, Kobor MS. Population-specificity of human DNA methylation. Genome Biol. 2012;13 (2):1–12.
39.
Gibbs JR, Van Der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai S-L, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6 (5):e1000952.PubMedPubMedCentral
40.
Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF, et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011;12 (1):1–13.
41.
Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38 (1):23–38.PubMed
42.
43.
Chambers JC, Loh M, Lehne B, Drong A, Kriebel J, Motta V, et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. Lancet Diabetes Endocrinol. 2015;3 (7):526–34.PubMedPubMedCentral
44.
Kulkarni H, Kos MZ, Neary J, Dyer TD, Kent JW Jr, Göring HH, et al. Novel epigenetic determinants of type 2 diabetes in Mexican-American families. Hum Mol Genet. 2015;24 (18):5330–44.PubMedPubMedCentral
45.
Florath I, Butterbach K, Heiss J, Bewerunge-Hudler M, Zhang Y, Schoettker B, et al. Type 2 diabetes and leucocyte DNA methylation: an epigenome-wide association study in over 1,500 older adults. Diabetologia. 2016;59 (1):130–8.PubMed
46.
Al Muftah WA, Al-Shafai M, Zaghlool SB, Visconti A, Tsai P-C, Kumar P, et al. Epigenetic associations of type 2 diabetes and BMI in an Arab population. Clin Epigenet. 2016;8 (1):1–10.
47.
Juvinao-Quintero DL, Marioni RE, Ochoa-Rosales C, Russ TC, Deary IJ, Van Meurs JB, et al. DNA methylation of blood cells is associated with prevalent type 2 diabetes in a meta-analysis of four European cohorts. Clin Epigenet. 2021;13 (1):1–14.
48.
Cardona A, Day FR, Perry JR, Loh M, Chu AY, Lehne B, et al. Epigenome-wide association study of incident type 2 diabetes in a British population: EPIC-Norfolk study. Diabetes. 2019;68 (12):2315–26.PubMedPubMedCentral
49.
Nuotio M-L, Pervjakova N, Joensuu A, Karhunen V, Hiekkalinna T, Milani L, et al. An epigenome-wide association study of metabolic syndrome and its components. Sci Rep. 2020;10 (1):1–12.
50.
Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, et al. A novel epigenetic signature for early diagnosis in lung cancer. Clin Cancer Res. 2016;22 (13):3361–71.PubMed
51.
Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004;4 (9):707.PubMed
52.
Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn. 2012;12 (5):473–87.PubMed
53.
Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology. 2018;6 (03no4):79–100.PubMed
54.
Romanowska J, Haaland ØA, Jugessur A, Gjerdevik M, Xu Z, Taylor J, et al. Gene–methylation interactions: discovering region-wise DNA methylation levels that modify SNP-associated disease risk. Clin Epigenet. 2020;12 (1):1–18.
55.
56.
Fan C-T, Lin J-C, Lee C-H. Taiwan Biobank: a project aiming to aid Taiwan’s transition into a biomedical island. 2008.
57.
Lin J-C, Fan C-T, Liao C-C, Chen Y-S. Taiwan Biobank: making cross-database convergence possible in the Big Data era. Gigascience. 2018;7 (1):gix110.
58.
Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 (Supplement 1):S81–90.
59.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42 (6):1206–52.PubMed
60.
Wei C-Y, Yang J-H, Yeh E-C, Tsai M-F, Kao H-J, Lo C-Z, et al. Genetic profiles of 103,106 individuals in the Taiwan Biobank provide insights into the health and history of Han Chinese. NPJ Genom Med. 2021;6 (1):1–10.
61.
Meigs JB, Cupples LA, Wilson P. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes. 2000;49 (12):2201–7.PubMed
62.
Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance–a population-based twin study. Diabetologia. 1999;42 (2):139–45.PubMed
63.
Maher B. Personal genomes: the case of the missing heritability. Nat News. 2008;456 (7218):18–21.
64.
Boks MP, Derks EM, Weisenberger DJ, Strengman E, Janson E, Sommer IE, et al. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS ONE. 2009;4 (8):e6767.PubMedPubMedCentral
65.
Kaminsky ZA, Tang T, Wang S-C, Ptak C, Oh GH, Wong AH, et al. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet. 2009;41 (2):240–5.PubMed
66.
Baroni MG, Alcolado JC, Gragnoli C, Franciosi AM, Cavallo MG, Fiore V, et al. Affected sib-pair analysis of the GLUT1 glucose transporter gene locus in non-insulin-dependent diabetes mellitus (NIDDM): evidence for no linkage. Hum Genet. 1994;93 (6):675–80.PubMed
67.
Alcolado J, Baroni M. Restriction fragment length polymorphisms at the GLUT4 and GLUT1 gene loci in type 2 diabetes. Diabet Med. 1992;9 (1):58–60.PubMed
68.
Elbein SC, Hoffman MD, Matsutani A, Permutt MA. Linkage analysis of GLUT1 (HepG2) and GLUT2 (liver/islet) genes in familial NIDDM. Diabetes. 1992;41 (12):1660–7.PubMed
69.
Li S, Oelbaum R, Baroni M, Stock J, Galton D. Association of genetic variant of the glucose transporter with non-insulin-dependent diabetes mellitus. Lancet. 1988;332 (8607):368–70.
70.
Ghafar MTA, Shalaby KH, Okda HI, Rizk FH. Association of ABCA1 (C69T) gene polymorphism with dyslipidemia and type 2 diabetes among the Egyptian population. Meta Gene. 2020;25:100714.
71.
Minn AH, Pise-Masison CA, Radonovich M, Brady JN, Wang P, Kendziorski C, et al. Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2005;336 (3):770–8.PubMed
72.
Mohammad Alhawiti N, Al Mahri S, Azhar Aziz M, Shafi Malik S, Mohammad S. TXNIP in metabolic regulation: physiological role and therapeutic outlook. Curr Drug Targets. 2017;18 (9):1095–103.PubMed
73.
Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and β-cell apoptosis. Diabetes. 2008;57 (4):938–44.PubMed
Metadata
Title
Interaction between a diabetes-related methylation site (TXNIP cg19693031) and variant (GLUT1 rs841853) on fasting blood glucose levels among non-diabetics
Authors
Hao-Hung Tsai
Chao-Yu Shen
Chien-Chang Ho
Shu-Yi Hsu
Disline Manli Tantoh
Oswald Ndi Nfor
Shin-Lin Chiu
Ying-Hsiang Chou
Yung-Po Liaw
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Epigenetics
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03269-y

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation

Research

Markers of endothelial glycocalyx dysfunction in Clarkson disease

Research

Elevated mid-trimester 4-h postprandial triglycerides for predicting late-onset preeclampsia: a prospective screening study

Research

Inhibition of NOS1 promotes the interferon response of melanoma cells

Research

Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway

Research

C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits